Renal Impairment Hampers Bisphosphonate Treatment in a Quarter of Lung Cancer Patients with Bone Metastasis

Katalin Fabian, Rita Puskás, Tímea Kakuk, László Prés, Dorottya Fejes, Zsolt Szegedi, Lívia Rojkó, Zoltan Imre Szallasi, Balázs Döme, Orsolya Pipek, Judit Moldvay*

*Corresponding author for this work

    Research output: Contribution to journalJournal articleResearchpeer-review

    189 Downloads (Pure)

    Abstract

    Renal function impairment in lung cancer patients with bone metastases was investigated, as this can limit the application of bisphosphonates representing the gold standard in the management of such cases. Clinicopathological data of 570 lung cancer patients were retrospectively analysed for changes in renal function parameters. Co-morbidities included hypertension (50%), COPD (33%) and diabetes mellitus (15%). Statistical analysis was performed with Fisher's exact tests and a Cox proportional hazards model. In patients suffering from hypertension, both median serum creatinine and blood urea nitrogen (BUN) were higher (81.9 versus 75.8 μmol/l, p
    Original languageEnglish
    JournalBasic & Clinical Pharmacology & Toxicology
    Volume122
    Issue number1
    Pages (from-to)126-132
    ISSN1742-7835
    DOIs
    Publication statusPublished - 2017

    Keywords

    • Lung cancer
    • Bisphosphonate treatment
    • Bone metastasis
    • Renal function

    Cite this

    Fabian, K., Puskás, R., Kakuk, T., Prés, L., Fejes, D., Szegedi, Z., Rojkó, L., Szallasi, Z. I., Döme, B., Pipek, O., & Moldvay, J. (2017). Renal Impairment Hampers Bisphosphonate Treatment in a Quarter of Lung Cancer Patients with Bone Metastasis. Basic & Clinical Pharmacology & Toxicology, 122(1), 126-132. https://doi.org/10.1111/bcpt.12876